Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

184.89
0.0000
Post-market: 182.00-2.8900-1.56%19:30 EDT
Volume:440.10K
Turnover:81.72M
Market Cap:10.91B
PE:-56.97
High:187.60
Open:185.00
Low:183.68
Close:184.89
52wk High:191.62
52wk Low:73.16
Shares:58.98M
Float Shares:56.44M
Volume Ratio:0.65
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2456
EPS(LYR):-3.2819
ROE:-25.98%
ROA:-5.18%
PB:15.98
PE(LYR):-56.34

Loading ...

Glaukos Completes Enrollment in 510(k) Pivotal Study of Preserflo MicroShunt for Advanced Glaucoma Patients

Reuters
·
Jul 27

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for Preserflo™ Microshunt

THOMSON REUTERS
·
Jul 27

Earning Preview: Glaukos revenue is expected to increase by 30.68% this quarter, and institutional views are bullish

Earnings Agent
·
Jul 22

Glaukos CFO Alex R. Thurman Disposes of USD 1.6 Million in Common Shares

Reuters
·
Jul 22

Glaukos (GKOS) Could Be 1% Undervalued After Its Pipeline Growth Narrative

Simply Wall St.
·
Jul 17

Glaukos is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 17

Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating

MT Newswires Live
·
Jul 16

Mobia Medical Names Reza Zadno to Board as Independent Director

Reuters
·
Jul 16

Glaukos CFO Alex R. Thurman Sells 10,000 Shares for $1.55 Million

Reuters
·
Jul 14

Glaukos Chief Development Officer Tomas Navratil Disposes of 716 Shares for $99,571.96

Reuters
·
Jul 09

Glaukos is Maintained at Buy by Citigroup

Dow Jones
·
Jul 08

Press Release: Glaukos to Release Second Quarter 2026 Financial Results After Market Close on July 29

Dow Jones
·
Jul 08

Glaukos price target raised to $175 from $162 at Citi

TIPRANKS
·
Jul 08

Glaukos: Favorable iDose Reimbursement Outlook and Epioxa Launch Drive Attractive Risk-Reward, Supporting Buy Rating

TIPRANKS
·
Jul 08

Citi Sticks to Its Buy Rating for Glaukos (GKOS)

TIPRANKS
·
Jul 08

Glaukos Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 06

Glaukos Corporation : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $168

THOMSON REUTERS
·
Jul 06

Glaukos Price Target Maintained with a $165.00/share by Piper Sandler

Dow Jones
·
Jul 01

Analysts Conflicted on These Healthcare Names: Alumis Inc. (ALMS), Glaukos (GKOS) and Regeneron (REGN)

TIPRANKS
·
Jul 01

Glaukos Completes Enrollment in Phase 2 Trial of Glk-321 for Demodex Blepharitis

Reuters
·
Jun 25